ABSTRACTS

The International Society of Glomerular Disease (ISGD) invites the submission of abstracts for the Inaugural Clinical Trials Summit. This summit is dedicated to transforming the future of kidney disease research by accelerating the design and execution of innovative, patient-centered clinical trials in glomerular disease and beyond.

I. Conference Theme and Focus

Theme: Pathways to Progress: UNITING VISION, SCIENCE, AND PARTNERSHIP TO ACCELERATE KIDNEY CURES

Abstracts should align with the Summit's mission to produce tangible, actionable outputs and advance the field through scientific rigor and cross-sector collaboration.

Abstracts may be selected for poster presentation or short talks.

Key Topics for Submission

Submissions are encouraged across the entire spectrum of kidney clinical trials innovation, with a focus on glomerular disease and on:

• Clinical Trial Design and Methodology: Innovative and adaptive trial designs, decentralized trial models, and methods to enhance trial efficiency.
• Biomarker and Endpoint Validation: Novel and surrogate endpoints, validation strategies for new biomarkers, and efforts toward regulatory endpoint harmonization.
• Patient Stratification and Diversity: Strategies for patient-centered trial design, improving patient diversity and inclusivity in research, and addressing barriers to recruitment.
• Therapeutic Development Pathways: Novel drug target identification, early-phase trial results for kidney disease, and strategies for accelerating therapeutic pipelines.
• Regulatory and Policy Alignment: Submissions addressing regulatory barriers, policy recommendations, and strategies for cross-stakeholder alignment.
• Implementation Science: Practical applications and frameworks for implementing novel trial methodologies and addressing operational challenges.

II. Target Audience

The Summit is designed to convene diverse stakeholders, and abstracts should have relevance to one or more of the following groups:

• Clinical Trialists and Investigators
• Nephrologists and Clinician-Scientists
• Biopharma/Biotech Trial Sponsors
• Regulatory Professionals
• Patient Advocacy Leaders
• Emerging Researchers and Trainees

III. Submission Requirements and Format

Submissions must represent original work. Unpublished work (or work not yet presented at a major meeting) is highly encouraged, but “encore” submissions will be considered.

Please submit all abstracts using the official submission form. Submissions via other means will not be accepted.

Structure

Abstracts must be structured with the following sections:

1. Title: Concise and clearly reflects the content.
2. Authors/Affiliations: Full names and institutional affiliations for all contributors. The presenting author must be present at the conference.
3. Introduction: Brief background and statement of the problem/challenge.
4. Methods: Description of the study design, trial, or framework developed.
5. Results/Findings: Clear presentation of key data, outcomes, or conclusions.
6. Conclusion/Actionability: Summary of the work's impact and its contribution to improving kidney clinical trials.

Technical Specifications

• Word Count: The abstract body (Introduction through Conclusion/Actionability) must not exceed 350 words.
• Tables/Figures: Abstracts will not include tables/figures.
• Conflict of Interest/Financial Disclosures: Required for the presenting author.

IV. Key Dates and Location

V. Review and Selection Criteria

Abstracts will be peer-reviewed and selected based on the following criteria, in alignment with the Summit's goals:

• Scientific Rigor and Innovation: Quality of the science and the novelty of the approach or findings.
• Relevance to Summit Goals: Direct relation to identifying and addressing pressing barriers related to key topics of the summit.
• Actionability and Impact: Potential to produce "action items," frameworks, or consensus strategies that can be implemented to advance kidney health outcomes.
• Clarity and Presentation: The abstract is well-written, concise, and logically organized.